aTyr Pharma Reports Q1 2025 Financial Results with $14.9 Million Net Loss

aTyr Pharma, Inc. reported its financial results for the first quarter of 2025, revealing a consolidated net loss of $14.9 million, a slight improvement from the $15.5 million loss recorded in the same period of 2024. The company did not generate any revenue during the quarter, a significant decrease from the $235,000 reported in the first quarter of the previous year, primarily due to the absence of license and collaboration agreement revenues. Operating expenses for the quarter totaled $15.8 million, down from $16.9 million in the prior year, driven by reduced research and development costs, which fell to $11.8 million from $13.4 million.

In terms of financial position, aTyr Pharma's total assets increased to $97.2 million as of March 31, 2025, compared to $96.8 million at the end of 2024. The company’s cash and cash equivalents decreased to $10.4 million from $11.1 million, while available-for-sale investments rose to $66 million from $61 million. The company’s accumulated deficit reached $546.9 million, reflecting ongoing investments in its clinical development programs, particularly for its lead candidate, efzofitimod.

During the quarter, aTyr Pharma successfully raised approximately $18.8 million through the issuance of 4,941,895 shares of common stock under its at-the-market offering program with Jefferies LLC. This capital infusion is expected to support the company’s ongoing clinical trials and operational needs. The company’s employee headcount increased to 89, up from 84 at the end of 2024, indicating a strategic focus on expanding its workforce to support its research and development efforts.

Operationally, aTyr Pharma continues to advance its clinical programs, particularly the EFZO-FIT study, a pivotal Phase 3 trial evaluating efzofitimod for pulmonary sarcoidosis. The study has exceeded its enrollment target, with 268 patients enrolled, and topline data is anticipated in the third quarter of 2025. The company is also exploring additional indications for efzofitimod, including systemic sclerosis-associated interstitial lung disease, through its EFZO-CONNECT study, which is set to report interim data in the second quarter of 2025.

Looking ahead, aTyr Pharma anticipates continued net losses as it invests in the development of efzofitimod and other potential therapies based on tRNA synthetase biology. The company has indicated that it will need to secure additional funding through equity offerings, collaborations, or licensing arrangements to support its operations and clinical development activities. As of March 31, 2025, aTyr Pharma believes its existing cash and investments will be sufficient to meet its material cash requirements for at least the next year.